In this episode of Boston Scientific Talks, Peter Pattison, President, Interventional Oncology, and Liza Davis, VP of R&D, Interventional Oncology, share insights into the acquisition of Obsidio and the integration of its unique gel embolic material technology into Boston Scientific's portfolio.

The technology, described as a "conformable solid," offers a unique balance between a liquid and solid embolic, providing physicians with precise control and rapid occlusion during interventional oncology procedures. The discussion also covers the successful transition from FDA approval to commercialization, with Obsidio technology already being used in several cases. Looking ahead, Pattison and Davis discuss the potential for further applications of the technology and its integration with Boston Scientific's new coil products.

This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.com/medical.

Thank you for listening to the Boston Scientific Talks Podcast.

Subscribe to this podcast on every major podcast platform.

How Boston Scientific's acquisition of Obsidio is shaping its interventional oncology business

The DeviceTalks Podcast Network delivers news, insights and commentary from Medtech industry leaders. Our podcasts will inspire medtech professionals to create better medtech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 8 podcasts:

• AbbottTalks
• AI Meets Life Sci
• Boston Scientific Talks
• DeviceTalks Weekly
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

Technology

Tech News

Podcasting

Gadgets

Software How-To

In this episode, the DeviceTalks Editorial Team - Tom Salemi, Kayleen Brown - recaps the highlights of DeviceTalks Boston with MassDevice Editor in Chief Chris Newmarker, Holly Scott of the Mullings Group, and Paul Melnychuck, Vice President & General Manager, Advanced Components at Spectrum Plastics Group, A DuPont Business.

Spectrum Plastics Group sponsored the podcast. For more information go to SpectrumPlastics.com.

Please subscribe to the DeviceTalks Podcast Network.

Hear the Final Word About DeviceTalks Boston: Live Recording of DeviceTalks Weekly On Stage

In this episode of AbbottTalks, Mahmood Kazemi, MD, Chief Medical Officer of Abbott’s Diabetes Care business overviews the profound advancements in diabetes management over the past decade and discusses the evolution of treatments and technological innovations that have revolutionized how individuals with diabetes approach their condition.

Further, Dr. Kazemi underscores the benefits of advancements such as the GLP-1 receptor agonists and medications that control glucose levels and offer cardiovascular and renal protection. He then elaborates on how Abbott's FreeStyle Libre continuous glucose monitoring (CGM) systems have significantly improved diabetes management. These systems provide real-time data, empowering individuals to customize their medication, diet, and activity levels with unprecedented precision. He also speaks to Abbott's ongoing and future work, including developing a state-of-the-art continuous glucose ketone monitoring (CGKM) sensor. This medical biowearable is designed to provide crucial early warning signs in Type 1 diabetes management, a significant step towards preventing dangerous complications and hospitalizations.

Looking to the future, Kazemi anticipates a wider adoption of CGM across the diabetes community, including those with type 2 diabetes, and an increase in insurer coverage.

Thank you to BMP Medical for sponsoring this episode of AbbottTalks! For more information on how BMP Medical works with medical device companies, visit www.bmpmedical.com

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Kazemi discusses a decade of diabetes advancements and the impact of CGM on diabetes care

In this week’s episode of the DeviceTalks Weekly Podcast, Editorial Director Tom Salemi talks about next week’s DeviceTalks Boston meeting with MedTech Innovator CEO Paul Grand.

We also hear interviews done earlier this year with speakers – Bertin Nahum of Quantum Surgical, Kurt Haggstrom of Synchron and Closing Keynote Speaker Rajit Kamal of Medtronic.

Anyone interested attending – and meeting a surprise surgical robotics guest – can register at Boston.DeviceTalks.com. Use the code DTWeekly25 to save 25% of the registration fee.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network.

It's Here! Share Your Story at DeviceTalks Boston Next Week Where You Can Meet Great Medtech Leaders

In the final episode of MedtechWOMEN Talks season one, we are joined by YJ Oh, SVP US Sales, Marketing and Commercial Operations at Edwards Lifesciences, who takes us through the intricate process of medical device commercialization. Starting with her unique entry into the medtech industry, YJ shares her comprehensive journey from sales to global marketing, emphasizing the significant role of upstream marketing in shaping product development and downstream efforts in executing commercial strategies.

In the discussion, YJ highlights the criticality of understanding market needs right from the inception of a product idea, ensuring that every development phase aligns with customer insights and real-world applicability. She provides a glimpse into the key collaborations across various departments and touches on the essential feedback mechanisms in place, ensuring devices meet the stringent requirements and expectations set forth by both regulatory bodies and the end-users, primarily physicians. Her insights extend into the strategic considerations for global market penetration, discussing how different regulatory landscapes affect the accessibility and success of medical devices across borders.

TL;DR – Key Takeaways:
- The integration of market insights from the beginning is crucial for successful medical device commercialization.
- Collaborative efforts across various functions are vital to address the comprehensive demands of product development.
- Strategic global considerations are imperative to navigate varying regulatory and market conditions effectively.

Thank you to our season one sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical!

https://aptyx.com/ 
https://catalyzehealthcare.com/ 
https://confluentmedical.com/
https://www.cretex.com/

Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

Thank you for listening to MedtechWOMEN Talks!

How do I take an approved medical device to market? with YJ Oh, Edwards Lifesciences

In this episode, we visit with Rebecca Seidel, president of Medtronic’s cardiac ablation solutions group, about the future of pulsed-field ablation and what it means for the electrophysiology sector.

Host Tom Salemi also visits with biomedical researcher Jeff Karp to discuss his new book, LIT: Life Ignition Tools: Use Nature's Playbook to Energize Your Brain, Spark Ideas, and Ignite Action Kindle Edition. Use the code LIT25 to save 25% off the registration price of DeviceTalks Boston and you could win a free copy. Karp will also be at DeviceTalks Boston’s opening reception on April 30. Come meet the author and noted medtech innovator. 

Finally, we get a #DTBoston2024 speaker preview – Scott Nelson, CEO of FastWave Medical, one of two IVL companies we’ll have at the conference!

Thank you to Freudenberg Medical for sponsoring this episode. Go to Freudenbergmedical.com for more information.

Thank you for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network

How Boston Scientific's acquisition of Obsidio is shaping its interventional oncology business

Download our free app to listen on your phone